Good morning, everyone, and how are you today? We hope the weekend was refreshing and memorable. Now, though, the routine has resumed. Yes, we are referring to those meetings and deadlines that await. We are, of course, coping by brewing that treasured cup of stimulation that we so adore. Please feel free to join us. After all, what better way to attack the workload? Meanwhile, here are some tidbits. Hope your day goes well and stay in touch...
Roche Offers Pay-For-Performance Avastin Plan In Germany (Reuters)
Cubist Pharmaceutical To Buy Adolor for $190M (Bloomberg News)
Chinese Dairy May Bid For Pfizer Infant Nutrition Biz (Bloomberg News)
Abbott May Pay $1.3B Fine For Depakote Marketing (Bloomberg News)
Biogen And Abbott Say MS Drug Reduced Relapse Rate (Associated Press)
Novartis Psoriasis Drug Helps With Symptoms: Study (Reuters)
NJ Labor Dept Announces $3.6M In Retraining Grants For Pharma Workers (NJ Biz)
Australian Watchdog Probes Pfizer Payments To Pharmacies (Sydney Morning Herald)
FDA Plans Quality-By-Design To Cut Clinical Costs (Outsourcing Pharma)
Doctors Didn't Disclose Spine Product Cancer Risk In Journal (Milwaukee Journal Sentinel)
Corden Pharma Lays Off 60 Employees (Boulder County Business Report)
Pharmaxis Gets OK In Europe For Cystic Fibrosis Drug (Herald Sun)
EDITOR'S NOTE: Please check this post for updates throughout the morning
Coffee pix thx to chichcacha flickr creative commons
1 Comment
Dr Janet Woodcock promises Quality-By-Design implementation at FDA by 2036. QBD in the US began with Edwards Deming advising Ford Motor Company in 1982 and in Japan long before that. If my math is correct it will have taken FDA only 54 years to come around. Bout right for them.